General Psychiatry
General Psychiatry RSS Feed RSS

Antipsychotics and Anticonvulsants for Anxiety Disorders

September 1, 2013
Steve Balt, MD, MS
Steve Balt, MD, MS Board Member, The Carlat Report. In private practice in the San Francisco Bay area. Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America.
We know how frequently our patients complain of anxiety. Anxiety disorders are common, chronic conditions. They also increase the risk for mood and substance disorders, and complaints of anxiety are found in a wide range of other psychiatric and medical conditions, as well.
Read More
EXPERT Q&A

Anxiety Disorders in DSM-5 and Beyond

September 1, 2013
Daniel Pine, MD

PineDanielMD_headshot.pngDaniel Pine, MD

Chief, Section on Development and Affective Neuroscience, National Institute of Mental Health, Chair, DSM-5 Work Group on Child and Adolescent Psychiatric Disorders Dr. Pine has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Dr Daniel Pine, chief of the section on Development and Affective Neuroscience at the NIMH and chair of the DSM-5 Work Group on Child and Adolescent Psychiatric Disorders discusses anxiety disorders in the current and future state of anxiety disorder research and practice.
Read More
RESEARCH UPDATE

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

September 1, 2013
Glen Spielmans, PhD

Section editor, Glen Spielmans, PhD

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission?
Read More
NEWS OF NOTE

Fetzima Approved for Depression

September 1, 2013
In July 2013, the FDA approved the SNRI Fetzima (levomilnacipran) for major depressive disorder (MDD) in adults (Forest Laboratories, Inc). The efficacy of Fetzima at doses 40 mg to 120 mg once daily was established in three, eight-week, randomized, double-blind, placebo-controlled studies in adults diagnosed MDD.
Read More

OTC Agents for Depression, Anxiety, and Insomnia

July 1, 2013
Cara Hoepner, NP
Cara Hoepner, NP psychiatric nurse practitioner and Clinical Specialist, San Francisco, CA Ms. Hoepner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
More than 38% of Americans use complementary and alternative medicine (CAM) yearly, with 12.7% using so-called “natural products." More than a third of people over age 50 report use of supplements, yet only about half have discussed this with their doctors.
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
  • shutterstock_2635946985.jpg
    General Psychiatry

    AI in Practice

    Listen now
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.